Liver News and Research

RSS

LOX enzyme can create scarred microenvironment that enhances cancer spreading

What to fear most if faced by a cancer diagnosis is the spread of the cancer to other parts of the body. This process called metastasis accounts for over 90% of cancer patient deaths and therefore is a strong focus for cancer researchers.

28 Jan 2013

IRHOM2-targeted drugs can effectively treat patients with rheumatoid arthritis

Researchers at Hospital for Special Surgery have identified a potential new target for drugs to treat patients with rheumatoid arthritis (RA), a protein known as IRHOM2. The finding could provide an effective and potentially less toxic alternative therapy to tumor necrosis factor-alpha blockers (TNF-blockers), the mainstay of treatment for rheumatoid arthritis, and could help patients who do not respond to this treatment. Efforts to develop drugs that hone in on this new target are underway.

28 Jan 2013

Takeda receives FDA approval for Nesina, Kazano and Oseni to treat type 2 diabetes

The U.S. Food and Drug Administration today approved three new related products for use with diet and exercise to improve blood sugar control in adults with type 2 diabetes: Nesina (alogliptin) tablets, Kazano (alogliptin and metformin hydrochloride) tablets, and Oseni (alogliptin and pioglitazone) tablets.

28 Jan 2013

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

27 Jan 2013

Undetected comorbidities linked to increased mortality in schizophrenia

Patients with schizophrenia have elevated mortality, the leading causes of which appear to be ischemic heart disease and cancer, a Swedish national cohort study shows.

25 Jan 2013

Antibiotic use common at the end of life

More than one-quarter of hospice patients receive antibiotics in their last week of life, despite the absence of documented infection in most cases, US researchers report.

25 Jan 2013

Gastrointestinal, liver effects common after doxycycline in cats

Doxycycline, an antibiotic derivative of tetracycline, commonly results in adverse gastrointestinal side effects and increased liver enzyme activity in cats, report German researchers.

25 Jan 2013

Researchers identify cancer-associated mutations

Two new mutations that collectively occur in 71 percent of malignant melanoma tumors have been discovered in what scientists call the "dark matter" of the cancer genome, where cancer-related mutations haven't been previously found.

25 Jan 2013

Mice exposed to BPA exhibit spontaneous activity, have leaner body mass

Female mice exposed to Bisphenol A through their mother's diet during gestation and lactation were found to be hyperactive, exhibit spontaneous activity and had leaner body mass than those not exposed to the chemical, researchers at the University of Michigan School of Public Health have discovered.

25 Jan 2013

Early-life exposure to TBT chemical can cause obesity

Exposing pregnant mice to low doses of the chemical tributyltin (TBT) - which was used in marine antifouling paints and is used as an antifungal agent in some paints, certain plastics and a variety of consumer products - can lead to obesity for multiple generations without subsequent exposure, a UC Irvine study has found.

25 Jan 2013

Women taking tacrolimus drug can breast feed their babies

Women taking the immunosuppressant tacrolimus can rest assured that breast feeding will not elevate their babies' exposure to the drug, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).

24 Jan 2013

Clinical trial to evaluate cyclodextrin against Niemann-Pick disease type C1

A clinical trial to evaluate a drug candidate called cyclodextrin as a possible treatment for Niemann-Pick disease type C1 (NPC), a rare and fatal genetic disease, will start today, researchers announced.

24 Jan 2013

Novartis receives FDA approval for Exjade to treat chronic iron overload in NTDT patients

The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).

23 Jan 2013

Galectin Therapeutics' GR-MD-02 reverses diabetic nephropathy in preclinical study

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced new preclinical data on the efficacy of anti-galectin therapy on diabetic kidney disease.

23 Jan 2013

Intestinal bacteria can produce biochemicals and hormones that stop development of diabetes

All humans have enormous numbers of bacteria and other micro-organisms (10 to 14) in the lower intestine. In fact our bodies contain about ten times more bacteria than our own cells and these tiny passengers are extremely important for our health. They help us digest our food and provide us with energy and vitamins.

19 Jan 2013

Leprosy bacteria able to change the make-up of Schwann cells

A discovery about the way in which bugs spread throughout the body could help to develop stem cell treatments.

19 Jan 2013

$ADT increases risk of fracture incidence after treatment completion in men with prostate cancer$

ADT increases risk of fracture incidence after treatment completion in men with prostate cancer

In what is believed to be the first study to describe the impact on men with a 'high' risk of bone fracture who are receiving long-term androgen deprivation therapy (ADT) for prostate cancer, new research from The Cancer Institute of New Jersey shows this population to have a higher fracture incidence following treatment completion.

18 Jan 2013

Boehringer Ingelheim initiates enrollment in Phase III IFN-free HCV trial

Today, Boehringer Ingelheim announced that the first patients have been enrolled in the company's pivotal Phase III interferon (IFN)-free hepatitis C (HCV) clinical trial programme, HCVerso.

18 Jan 2013

Octapharma receives FDA approval for Octaplas to treat blood clotting disorders

The U.S. Food and Drug Administration today approved Octaplas, a pooled plasma (human) blood product for the replacement of clotting proteins (coagulation factors) in certain medical conditions where patients have insufficient levels.

18 Jan 2013

Report: Cancer death rates decline 20% from its peak in 1991

As of 2009, the overall death rate for cancer in the United States had declined 20 percent from its peak in 1991, translating to the avoidance of approximately 1.2 million deaths from cancer, 152,900 of these in 2009 alone. These figures come from the American Cancer Society's annual Cancer Statistics report, one of the most widely-cited medical publications in the world.

17 Jan 2013